Page 2444 - Williams Hematology ( PDFDrive )

2415
2414 Index Index 2415

atypical, 1279 phenotypic expression, 1283–1284 response to, 1452t, 1454–1456, 1455t,
clinical features, 1445 progression, 1280–1281, 1464 1463
BCR-ABL1–positive thrombocythemia, related diseases without BCR secondary chromosomal changes
1449 rearrangement, 1467–1473, 1468t with, 1456
in children, 1445 atypical myeloproliferative disease, selection for initial therapy in chronic
concurrence of lymphoid malignancies, 1468t, 1472–1473 phase, 1454
1449 BCR rearrangement-negative vaccine, 423
extramedullary tumors, 1285 phenotypically typical chronic transformation to acute lymphoblastic
hyperleukocytic syndromes, 1285–1286, myelogenous leukemia, 1472–1473 leukemia, 1465–1466
1286t, 1449 chronic basophilic leukemia, 1279, 1470 Chronic myelogenous (myeloid) leukemia
marrow necrosis, 1287 chronic eosinophilic leukemia. See (CML) stem cell, 1439
metabolic signs, 1286–1287 Chronic eosinophilic leukemia Chronic myelomonocytic leukemia (CMML)
signs and symptoms, 1445 chronic myelomonocytic leukemia. See chromosomal abnormalities, 180t
splenomegaly, 1287, 1445 Chronic myelomonocytic leukemia clinical features, 1467–1468, 1468t
systemic symptoms, 1286 (CMML) differential diagnosis, 1450
thrombocytosis, 1311–1312 chronic neutrophilic leukemia, 1279, epidemiology, 1467
course and prognosis, 1462–1464, 1462t 1450, 1471–1472 gene mutations, 170, 1351, 1468t
definition and history, 1437–1438 juvenile myelomonocytic leukemia, monocytosis in, 1096
differential diagnosis, 1327, 1449–1450 1096, 1470–1471 Chronic natural killer cell lymphocytosis,
epidemiology, 1438, 1439f therapy 1197
etiology and pathogenesis, 1438–1445 in accelerated and blast crisis, 1466–1467 Chronic neutrophilic leukemia, 1279, 1450,
BCR-ABL1. See BCR-ABL1, in chronic busulfan, 1459 1468t, 1471–1472
myelogenous leukemia cytarabine, 1459 Chronic thromboembolic pulmonary
chromosomal abnormalities, 176–178, donor leukocyte infusion for hypertension, 2273
177f, 179t, 221t, 225, 230, 1278 posttransplantation relapse, 1462 CHS1, 1018
chronic myelogenous leukemia stem hematopoietic cell transplantation, Churg-Strauss syndrome. See Eosinophilic
cell, 1439 1460–1461, 1466–1467 granulomatosis with polyangiitis
coexistence of normal stem cells, 1440 high-dose chemotherapy with (EGPA)
environmental leukemogens, 1438 autologous stem cell infusion, 1460 Chuvash polycythemia
gene mutations, 230t hydroxyurea, 1459 clinical features, 510, 880
molecular pathology, 1441–1443, 1441f, for hyperuricemia, 1450 course and prognosis, 884
1442f for initial cytoreduction, 1450–1451 epidemiology, 873
origin from mutant hematopoietic stem interferon-α, 1459 etiology and pathogenesis, 876–877,
cell, 1438–1439 potential agents, 1459 877f
Ph chromosome, 1440 during pregnancy, 1459–1460 laboratory features, 881–882
pluripotential stem cell lesion, 1439–1440 radiation therapy, 1459 VHL mutations and, 510, 876–877, 877f,
progenitor cell characteristics, splenectomy, 1459, 1467 878f, 882t
1440–1441 tyrosine kinase inhibitors CID. See Combined immunodeficiencies
telomere length, 1444–1445 in accelerated phase and blast crisis, (CID)
laboratory features, 1445–1449 1466 Cigarette smoking
basophilia, 971, 972t adherence to therapy, 1456 acute myelogenous leukemia and, 1374
blood, 1445–1446, 1445f, 1446f, 1447t bosutinib, 339t, 1457–1458 adult Langerhans cell histiocytosis and,
chemical abnormalities, 1449–1450 comparison, 339t, 1451t 1108, 1109
cytogenetics, 1447, 1448f dasatinib, 176, 319t, 1453–1454, 1457 lymphoma and, 1573
eosinophilia, 955t, 1445 discontinuation of, 1460 myelodysplastic syndromes and, 1342
marrow, 1446–1447, 1446f disease progress and monitoring neutrophilia and, 1001
molecular probes, 1448–1449 during treatment, 1458–1459 persistent polyclonal lymphocytosis of
monocytosis, 1096 effect on rate of progression, 1464 B lymphocytes and, 1200
progenitor cell growth, 1447 after hematopoietic cell polycythemia and, 872, 876, 876t
minimal residual disease detection, transplantation, 1461–1462 porphyria cutanea tarda and, 906
1463–1464 imatinib, 176, 319t, 1451–1453, 1452t Cilostazol
minor-BCR breakpoint-positive, 1449 nilotinib, 176, 339t, 1454, 1457 antiplatelet effects, 404
neutrophilic, 1449 pharmacology, 338–341 clinical uses, 404t, 405
pathogenesis, 1282 ponatinib, 339t, 1458 dosage, 404t
Ph-chromosome–positive acute resistance to. See Tyrosine kinase for peripheral arterial disease, 2297
myelogenous leukemia and, 1385 inhibitors, resistance to platelet effects, 2077–2078

Kaushansky_index_p2393-2506.indd 2415 9/21/15 3:21 PM